Cargando…
miR‐99a‐5p modulates doxorubicin resistance via the COX‐2/ABCG2 axis in triple‐negative breast cancer: from the discovery to in vivo studies
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759767/ https://www.ncbi.nlm.nih.gov/pubmed/35997029 http://dx.doi.org/10.1002/cac2.12352 |
| _version_ | 1784852305279975424 |
|---|---|
| author | Garrido‐Cano, Iris Adam‐Artigues, Anna Lameirinhas, Ana Blandez, Juan F. Candela‐Noguera, Vicente Rojo, Federico Zazo, Sandra Madoz‐Gúrpide, Juan Lluch, Ana Bermejo, Begoña Sancenón, Felix Cejalvo, Juan Miguel Martínez‐Máñez, Ramón Eroles, Pilar |
| author_facet | Garrido‐Cano, Iris Adam‐Artigues, Anna Lameirinhas, Ana Blandez, Juan F. Candela‐Noguera, Vicente Rojo, Federico Zazo, Sandra Madoz‐Gúrpide, Juan Lluch, Ana Bermejo, Begoña Sancenón, Felix Cejalvo, Juan Miguel Martínez‐Máñez, Ramón Eroles, Pilar |
| author_sort | Garrido‐Cano, Iris |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9759767 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-97597672022-12-20 miR‐99a‐5p modulates doxorubicin resistance via the COX‐2/ABCG2 axis in triple‐negative breast cancer: from the discovery to in vivo studies Garrido‐Cano, Iris Adam‐Artigues, Anna Lameirinhas, Ana Blandez, Juan F. Candela‐Noguera, Vicente Rojo, Federico Zazo, Sandra Madoz‐Gúrpide, Juan Lluch, Ana Bermejo, Begoña Sancenón, Felix Cejalvo, Juan Miguel Martínez‐Máñez, Ramón Eroles, Pilar Cancer Commun (Lond) Letters to the Editor John Wiley and Sons Inc. 2022-08-23 /pmc/articles/PMC9759767/ /pubmed/35997029 http://dx.doi.org/10.1002/cac2.12352 Text en © 2022 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat‐sen University Cancer Center. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Letters to the Editor Garrido‐Cano, Iris Adam‐Artigues, Anna Lameirinhas, Ana Blandez, Juan F. Candela‐Noguera, Vicente Rojo, Federico Zazo, Sandra Madoz‐Gúrpide, Juan Lluch, Ana Bermejo, Begoña Sancenón, Felix Cejalvo, Juan Miguel Martínez‐Máñez, Ramón Eroles, Pilar miR‐99a‐5p modulates doxorubicin resistance via the COX‐2/ABCG2 axis in triple‐negative breast cancer: from the discovery to in vivo studies |
| title | miR‐99a‐5p modulates doxorubicin resistance via the COX‐2/ABCG2 axis in triple‐negative breast cancer: from the discovery to in vivo studies |
| title_full | miR‐99a‐5p modulates doxorubicin resistance via the COX‐2/ABCG2 axis in triple‐negative breast cancer: from the discovery to in vivo studies |
| title_fullStr | miR‐99a‐5p modulates doxorubicin resistance via the COX‐2/ABCG2 axis in triple‐negative breast cancer: from the discovery to in vivo studies |
| title_full_unstemmed | miR‐99a‐5p modulates doxorubicin resistance via the COX‐2/ABCG2 axis in triple‐negative breast cancer: from the discovery to in vivo studies |
| title_short | miR‐99a‐5p modulates doxorubicin resistance via the COX‐2/ABCG2 axis in triple‐negative breast cancer: from the discovery to in vivo studies |
| title_sort | mir‐99a‐5p modulates doxorubicin resistance via the cox‐2/abcg2 axis in triple‐negative breast cancer: from the discovery to in vivo studies |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759767/ https://www.ncbi.nlm.nih.gov/pubmed/35997029 http://dx.doi.org/10.1002/cac2.12352 |
| work_keys_str_mv | AT garridocanoiris mir99a5pmodulatesdoxorubicinresistanceviathecox2abcg2axisintriplenegativebreastcancerfromthediscoverytoinvivostudies AT adamartiguesanna mir99a5pmodulatesdoxorubicinresistanceviathecox2abcg2axisintriplenegativebreastcancerfromthediscoverytoinvivostudies AT lameirinhasana mir99a5pmodulatesdoxorubicinresistanceviathecox2abcg2axisintriplenegativebreastcancerfromthediscoverytoinvivostudies AT blandezjuanf mir99a5pmodulatesdoxorubicinresistanceviathecox2abcg2axisintriplenegativebreastcancerfromthediscoverytoinvivostudies AT candelanogueravicente mir99a5pmodulatesdoxorubicinresistanceviathecox2abcg2axisintriplenegativebreastcancerfromthediscoverytoinvivostudies AT rojofederico mir99a5pmodulatesdoxorubicinresistanceviathecox2abcg2axisintriplenegativebreastcancerfromthediscoverytoinvivostudies AT zazosandra mir99a5pmodulatesdoxorubicinresistanceviathecox2abcg2axisintriplenegativebreastcancerfromthediscoverytoinvivostudies AT madozgurpidejuan mir99a5pmodulatesdoxorubicinresistanceviathecox2abcg2axisintriplenegativebreastcancerfromthediscoverytoinvivostudies AT lluchana mir99a5pmodulatesdoxorubicinresistanceviathecox2abcg2axisintriplenegativebreastcancerfromthediscoverytoinvivostudies AT bermejobegona mir99a5pmodulatesdoxorubicinresistanceviathecox2abcg2axisintriplenegativebreastcancerfromthediscoverytoinvivostudies AT sancenonfelix mir99a5pmodulatesdoxorubicinresistanceviathecox2abcg2axisintriplenegativebreastcancerfromthediscoverytoinvivostudies AT cejalvojuanmiguel mir99a5pmodulatesdoxorubicinresistanceviathecox2abcg2axisintriplenegativebreastcancerfromthediscoverytoinvivostudies AT martinezmanezramon mir99a5pmodulatesdoxorubicinresistanceviathecox2abcg2axisintriplenegativebreastcancerfromthediscoverytoinvivostudies AT erolespilar mir99a5pmodulatesdoxorubicinresistanceviathecox2abcg2axisintriplenegativebreastcancerfromthediscoverytoinvivostudies |